AstraZeneca's £450m investment in Liverpool's vaccine plant was a declared vote of confidence in the UK as a life sciences superpower amid a troubled industry-government relationship.
"Microfluidics has the potential to drive revolutionary changes across industries, delivering speed, efficiency, and precision, to help pave the way for the next generation of innovation in life sciences and technology," HP's President and CEO Enrique Lores wrote in a Department of Commerce press release.